June, 2019
MPNRF Under the Microscope
2018 Annual Report
It is important that we stop to reflect from time to time, and today we are lookin g back at the 2018 fiscal year. Our Annual Report  provides an opportunity to inform our community in mo re detail about our work. In addition to a report on how we invested our funds during the 2018 fiscal year, this year's Annual Report recognizes the thousands of individuals who s upported our mission with a gift December 1, 2017 - November 30, 2018.
Would you like your name to appear in the 2019 Annual Report as a supporter of our mission? Make a gift today!
Rare Disease Advocacy Summer 2019
Summer is here and Rare Across America has a unique opportunity to connect Members of Congress with their constituents who are living with a rare disease such as Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. Their program sets up meetings with advocates and Members of Congress or their staffers for a discussion on something YOU know well: what it is like to live with an MPN and what Congress could possibly do to help. 

No experience is necessary, and Rare Across America will prepare and train you for these meetings. Remember: no one knows your experience as a person with an MPN better than YOU! By connecting with your member of Congress you give a voice to the hundreds of thousands of people living with an MPN nationwide. 
In The News
5th Annual Women & MPN Conference

September 6, 2019
Boston, Massachusetts
Over the years, it became evident that the challenges endured by females with myelofibrosis, polycythemia vera, and essential thrombocythemia were particularly difficult. MPN Advocacy and Education International created a Women & MPN program to address those unique issues and encourage further exploration into issues facing women with MPNs. An annual conference focused on Women and MPN discusses the most up to date research and available resources and provides a venue for open dialogue between patients, caregivers, and experts.
Sierra Oncology Update
Sierra Oncology  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2, and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis.

According to the  FDA , "Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions."
Imago BioSciences, Inc.   announced that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases.
Promedior, Inc.  announced that positive safety and early efficacy clinical data was proven during their Phase 2 study of PRM-151 in myelofibrosis (MF) patients who were ineligible for Ruxolitinib or had failed the drug. Promedior looks forward to advancing the clinical program for PRM-151 in both MF and will explore other fibrotic indications in the future.
Participate in Research
Drug : CPI-0610
Company : Constellation Pharmaceuticals

Study name : A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With MF.

Enrolling : Patients with confirmed diagnosis of MF, DIPSS category of intermediate-1 or higher and Peripheral blood blast count <10%

To learn more click  here .
Drug : PU-H71
Company : Samus Therapeutics, Inc.

Study name : A Phase 1b Study to Assess the Safety, Tolerability of Oral PU-H71 in Subjects Taking Ruxolitinib.

Enrolling : Patients with confirmed diagnosis of PMF, Post-PV MF, or Post-ET MF, has been receiving ruxolitinib therapy, and evidence of evaluable residual burden of disease.

To learn more click  here .

MPN Updates from ASCO 2019
On June 4, the American Society of Clinical Oncology wrapped up their 2019 ASCO meeting held annually in Chicago, IL. Although ASCO does not focus solely on blood cancers, there were several updates pertaining to MPN related science. To read the abstracts of these updates, follow the link below.
Register for myMPN
Have you started your journey with myMPN yet? myMPN is an online registry for patients with ET, PV, and MF to share their stories and have a direct impact on MPN research. The data contributed by our community has been used in research to expedite the development of targeted disease therapies. Join today and be a part of the myMPN movement!
Upcoming July Events
There are several patient and caregiver events coming up in the month of July! Head over to our MPN Community Calendar on MPNRF's website and check out the many educational meetings and webinars taking place!
Do your shopping at smile.amazon.com and a percentage of what you spend will be donated to charity. Make sure to select the MPN Research Foundation as your institution of choice!